Deepak Bhatia

Position:

Professor of Pharmacogenomics

Location:

Health Professions Building 291

Phone:

(540) 542-6239

Email: dbhatia@su.edu

Employed Since:

2014

Educational History:
Ph.D. Pharmaceutical Sciences, West Virginia University, Morgantown, West Virginia 2007
M.S. Pharmaceutical Sciences, West Virginia University,Morgantown, West Virginia 2004
B. Pharm. Pharmacy, Bangalore University, India 1998

Fields of Expertise:

Cancer Biology: Oncogenes and tumor suppressor genes, cell cycle modulation, p53, cyclins, cyclin-dependent kinases, cyclin-dependent kinase inhibitors (Cip1/p21, Kip1/p27), apoptosis, and mitogenic and anti-apoptotic signaling pathways, transcription factors, cancer cell metabolism, miRNA.
Cancer Pharmacology: Chemoprevention of cancer by natural and synthetic agents – cellular, biochemical and molecular mechanisms employing biochemical and molecular biological techniques. Evaluation of cancer chemopreventive potential of dietary constituents employing several long-term animal tumor bioassay protocols, and short-term animal and cell culture assays. Therapy of cancer by natural and synthetic agents – cell culture studies and nude mice xenograft models. Cancer models include prostate, breast, lung and liver.
Epigenetic Pharmacology: Chemopreventive effects on chromatin regulation pathways such as histone acetylation and histone methylations and cross talk between post-transcriptional modifications.

Professional Highlights:

Dr. Bhatia is a professor in the Department of Pharmacogenomics in Bernard J Dunn School of Pharmacy, Shenandoah University in Fairfax campus, Virginia. Dr. Bhatia has extensive experience in pharmaceutical education, research and training medical, pharmacy and graduate students. Dr. Bhatia’s primary research interest encompasses cancer biology, cancer therapeutics and cancer prevention. His laboratory is associated with investigating mechanism-based chemopreventive and therapeutic effects of various medicinal plants, natural products, dietary and synthetic agents using various pre-clinical models of cancer.

Dr. Bhatia has extensively published original research papers and authoritative review articles, book chapters, and have presented over numerous papers at various national and international scientific meetings. Dr. Bhatia is the
Editor of two journals and has acted as guest editor of numerous journal thematic issues. Dr. Bhatia is likewise serving as an editorial board member and ad-hoc reviewer of many reputed journals.

Personal Highlights:

Invited Speeches:

Writing Stellar NIH Bio-sketch, APhA Annual Meeting Postgrad Forum Basic Science Speaker and a Panelist, Nashville, TN on March 16-19, 2018
Resveratrol-driven suicide gene therapy for non-small cell carcinoma. International Conference on Cancer Research and Targeted Therapy”, Holiday Inn Inner Harbor, Baltimore on October 21-23, 2016 (CRT-2016).
Transcriptional, post-transcriptional and epigenetic regulation of GADD45a. College of Pharmacy, Shree Guru Gobind Singh Tricentenary University, Gurgaon, India, July 28th, 2016.
Molecular basis of arsenic-induced lung cancer, School of Pharmacy, University of Charleston West Virginia, Charleston, WV, February 19, 2013.

Dr. Bhatia is a recipient of:

BJD Jr. Faculty research award. (2016-17)
Golden apple P2 teacher of the year. (2015-16)
BJD Jr. Faculty research award. (2014-15)